NCT00328432View on ClinicalTrials.gov

A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

December 31, 2005

Conditions
Breast Cancer
Interventions
DRUG

celecoxib 400 mg bid

Trial Locations (7)

35294

University of Alabama-Birmingham, Birmingham

43210

The Ohio State University, Columbus

44195

Cleveland Clinical Foundation, Cleveland

60153

Loyola University Medical Center, Maywood

66160

University of Kansas Medical Center, Kansas City

75246

US Oncology, Dallas

92262

MDDesert Comprehensive Breast Center, Palm Springs

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Kansas

OTHER

NCT00328432 - A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy | Biotech Hunter | Biotech Hunter